About Keratin, type I cuticular Ha5
Keratin, type I cuticular Ha5 (KRT35) is a protein
from Homo sapiens identified by UniProt accession
Q92764, 455 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | Keratin, type I cuticular Ha5 |
| UniProt accession | Q92764 |
| Gene | KRT35 |
| Organism | Homo sapiens |
| Length | 455 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (39)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- clear cell renal carcinoma · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- glioblastoma multiforme · score 0.18
- ovarian cancer · score 0.18
- breast adenocarcinoma · score 0.18
- thyroid gland adenocarcinoma · score 0.16
- esophageal cancer · score 0.14
- neuroblastoma · score 0.13
- low grade glioma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92764-F1 | alphafold | PREDICTED | 74.51 | — |
Amino-acid sequence (455 residues)
MASKCLKAGF SSGSLKSPGG ASGGSTRVSA MYSSSSCKLP SLSPVARSFS ACSVGLGRSS YRATSCLPAL CLPAGGFATS YSGGGGWFGE GILTGNEKET MQSLNDRLAG YLEKVRQLEQ ENASLESRIR EWCEQQVPYM CPDYQSYFRT IEELQKKTLC SKAENARLVV EIDNAKLAAD DFRTKYETEV SLRQLVESDI NGLRRILDDL TLCKSDLEAQ VESLKEELLC LKKNHEEEVN SLRCQLGDRL NVEVDAAPPV DLNRVLEEMR CQYETLVENN RRDAEDWLDT QSEELNQQVV SSSEQLQSCQ AEIIELRRTV NALEIELQAQ HSMRDALEST LAETEARYSS QLAQMQCMIT NVEAQLAEIR ADLERQNQEY QVLLDVRARL ECEINTYRGL LESEDSKLPC NPCAPDYSPS KSCLPCLPAA SCGPSAARTN CSPRPICVPC PGGRF
Explore Keratin, type I cuticular Ha5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets